Ozempic and Pregnancy: Safety, Risks, and Medical Guidance

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) is not recommended during pregnancy. Current clinical guidelines suggest discontinuing GLP-1 receptor agonists before conception or upon pregnancy confirmation due to insufficient safety data in human pregnancy and potential teratogenic effects observed in animal studies.

For women planning pregnancy or already expecting, understanding your metabolic risk profile and genetic predispositions can inform pre-conception discussions with your healthcare provider about safe glycemic management strategies tailored to your biology.

Why GLP-1 Receptor Agonists Are Avoided During Pregnancy

Animal reproduction studies with semaglutide showed adverse developmental effects at high doses. While human pregnancy data remains limited, regulatory agencies recommend discontinuation because the benefits do not clearly outweigh potential fetal risks in pregnant patients.

Pregnancy demands tight glycemic control to protect fetal development and maternal health. GLP-1 medications lack the established safety profile and long-term outcome data needed for first-line use in pregnant women, prompting reliance on insulin and other proven agents.

Evidence-Based Glycemic Management Options During Pregnancy

Pregnant women with type 2 diabetes or gestational diabetes require individualized glucose management. Current obstetric and endocrinologic guidelines recommend insulin as first-line therapy, alongside medical nutrition therapy and exercise, with close fetal and maternal monitoring throughout pregnancy.

Management Approach	Pregnancy Status	Efficacy Evidence	Provider Supervision
Insulin therapy	Established safety profile	Gold standard for tight glycemic control	High-intensity monitoring recommended
Medical nutrition therapy	Safe and effective adjunct	Reduces fasting and postprandial glucose	Registered dietitian collaboration
Physical activity modification	Safe with provider approval	Improves insulin sensitivity	Individualized activity plan
GLP-1 receptor agonists	Not recommended	Insufficient pregnancy safety data	Discontinue pre-conception or upon confirmation

Pre-Conception Planning: Understanding Your Metabolic Risk

Women considering pregnancy should assess their baseline glucose control, insulin resistance, and metabolic health months before conception. This allows time to optimize glycemic management, adjust medications to pregnancy-safe alternatives, and establish a care team experienced in maternal metabolic medicine.

Genetic factors influence how individuals respond to glucose-lowering interventions and metabolic stress during pregnancy. Understanding your predispositions in key metabolic pathways can help your provider design a personalized pre-conception and pregnancy management strategy.

When to Pause GLP-1 Treatment and What to Do Next

If you become pregnant while taking Ozempic or another GLP-1 medication, contact your healthcare provider immediately. Most guidelines recommend discontinuation, though your individual situation requires urgent clinical evaluation to minimize fetal exposure and transition to pregnancy-appropriate alternatives.

Post-pregnancy glycemic management may differ from pre-conception treatment. Some women resume GLP-1 therapy after delivery and breastfeeding completion; others may benefit from alternative agents based on updated metabolic assessment and personal health goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in GLP-1 receptor and metabolic pathways (including GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 variants). This information should be interpreted with a qualified healthcare provider to inform pre-conception conversations about your individual glycemic risk profile.

Understanding your genetic predispositions in peptide and metabolic signaling pathways does not predict exact medication response or pregnancy outcomes. Instead, these insights can support a more informed discussion with your reproductive endocrinologist or OB provider about tailored glycemic management before and during pregnancy.

For women planning pregnancy and currently using GLP-1 medications, comprehensive metabolic and genetic context can help your care team design a transition strategy that maintains glycemic control while minimizing fetal risk—ensuring both you and your baby have the best chance at optimal health.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.